Results 211 to 220 of about 1,044,602 (311)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Global Health Governance and the WHO Pandemic Agreement: A Scoping Review of Challenges and Analysis of Reforms. [PDF]

Int J Environ Res Public Health
Abdel-Motaal KA, El Kheir-Mataria WA, Chun S.   +2 more
europepmc   +1 more source

Understanding the Unoriginal: Indeterminant Originalism and Independent Interpretation of the Alaska Constitution [PDF]

, 2005
Schwaiger, Michael
core   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Comparing snowball sampling and RDS: A methodology and case study. [PDF]

PLoS One
Kim D, Gile KJ, Mathers B, Mirandola M, Gios L, Toskin I, Sabin KM.   +6 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes. [PDF]

Front Med Technol
Haon B, Hartmann M, Akodad S, Stevens H, Rochaix L.   +4 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Health concerns across the LGBTQIA+ spectrum. [PDF]

Sci Rep
Dar-Nimrod I, Barnish M.
europepmc   +1 more source

Niagara Frontier Transit Metro System and Metro-Link ADA Controllers Unit, International Brotherhood of Teamsters (IBT), Local 264 (2007) (MOA) [PDF]

, 2007

core   +1 more source